AzTrials
AzTrials

Necrotizing Soft Tissue InfectionNCT05032625

To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections

An observational study of Necrotizing Soft Tissue Infection, run by New York Medical College at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

There is significant mortality associated with necrotizing soft tissue infections, it is imperative to decrease mortality and complications associated with this disease is determined. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Necrotizing Soft Tissue Infection
What is being tested?
Surgery
Type of treatment
Surgery or procedure
How many people
13 participants
Where
1 siteUnited States
Study dates
1 Jul 2019to 1 Sep 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Adult, Older adult

Study population: All patients between 18 - 99 years of age who will undergo surgery for NSTI will be included in the study.

Who may be able to join

  • all patients ≥ 18 years presenting with necrotizing soft tissue infections admitted to Westchester Medical Center, who will undergo surgical management

Who cannot join

  • Age < 18 years.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Westchester Medical center

    Valhalla, New York, 10595

Other trials in United States

About this study

Official title: To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections- A Prospective Longitudinal Study

There is significant mortality associated with necrotizing soft tissue infections, it is imperative to decrease mortality and complications associated with this disease is determined. To accomplish this goal, study team will create a prospectively maintained database of all NSTI patients admitted at department of surgery. Investigators will asses the predictors of poor outcome and follow these patients for 1 year in clinic and asses the functional quality of life by incorporating 36-Item Short Form Survey (SF-36) score.

Read the detailed description

RATIONALE AND BACKGROUND Necrotizing soft tissue infections (NSTIs) are severe life-threatening, rapidly-spreading, soft tissue infections of the subcutaneous tissue, fascia, or muscle caused by bacteria. Due to the rapid progression of disease, early diagnosis and treatment are crucial to a patient's survival.

Given the aggressive nature of these infections and the significant mortality associated with them, it is imperative that the optimal standard of care to decrease mortality and complications associated with this disease is determined. To accomplish this goal, study team will create a prospectively maintained database of all NSTI patients admitted at department of surgery. Investigators will follow these patients for 1 year in clinic and asses the functional quality of life by incorporating 36-Item Short Form Survey (SF-36) score. This RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It is a validated scale freely available for research to assess the quality of life after surgery.

Primary Objectives:

The short term objectives are to evaluate 30-day mortality and to establish the predictors of poor outcome. The long term objectives are to measure quality of life after NSTI.

CHARACTERISTICS OF THE STUDY POPULATION

Target Population The study population will include all patients ≥ 18 years presenting with necrotizing soft tissue infections admitted to Westchester Medical Center, who will undergo surgical management

Subject Recruitment All patients admitted with a diagnosis of NSTI who undergo or about to undergo surgery for NSTI and meet initial screening criteria will be approached by the surgeon to determine if patient will agree to participate in the research study. The PI or PI approved research personnel will explain the study to the patient or their legally authorized representative (LAR). The patient/LAR will be given adequate time to ask questions and consider participation in this study. Should the patient agree to be in the study, the PI or PI-approved research personnel will have the patient/LAR fill out the consent and HIPAA forms and they will be given a copy of both documents.

Study Design This study will be a prospective observational study. There will be no study related interventions.

Study Duration Investigators aim to enroll approximately 300 subjects between three years. Each patient will be followed for 1 year. Therefore, we expect the study will be open for at least 4 years. 3 years for enrollment and 1 year to complete the data analysis and manuscript.

DATA PROCEDURES

  1. Data Collection Patients will be identified by the Department of Surgery morning report and by Emergency General Surgeons. The Emergency General Surgeons (listed at the beginning of the protocol), will notify the Department of Surgery's Clinical Research (DSCRU) unit when a patient meets study criteria. After obtaining consent, the patients will be followed up for one year. Data will be collected at the following time points: Pre-operative, Operative, Post-Operative ,2- month post-op, 4- months post-op, 8- months post-op and 1 year post-op.

Preoperative:

Demographics: age, sex, race and ethnicity Comorbidities: anemia, bleeding disorder, cancer, cardiac disease, chronic urinary tract infection, dialysis, hyperlipidemia, hypo/hyper-thyroidism, immunocompromised, prior infection, liver disease, obesity, peripheral vascular disease, renal disease, diabetes, hypertension and Transplant.

Social History: recreational drug use, tobacco and alcohol. Medications: use of anticoagulants and antiplatelets, Vitals: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), temperature (temp), respiratory rate (resp. rate), height, weight and BMI (body mass index, Modified frailty index (Mfi) and Charleston's comorbidity index Lab reports: the lab tests that are done as standard of care during the hospital stay will be collected. The following lab values will be collected for the study only if they are available in subject's medical record: hemoglobin, hematocrit, white blood count (differential), sodium, BUN (blood urea nitrogen), lactate, pH, glucose, creatinine, platelet count, histopathology and culture for microbiology of the tissues resected during surgery, coagulation profile (PT (prothrombin time)/PTT (partial thromboplastin time) /aPTT (activated partial thromboplastin time), cultures from blood, urine, sputum, trachea, wound and peritoneal fluid will be collected as well.

Intraoperative:

Duration of surgery: start time and end time Amount and type of fluids Received: IV fluids and blood products received General: Number of drains, planned/unplanned procedures and amount of blood loss Type and number/s of surgery: Time from admission to Ist debridement (days), time from admission to 2nd debridement (days), time from admission to 3rd debridement (days, time from admission to 4th debridement (days, time from admission to 5tht debridement (days), amputation of limb (Y/N). Wound size depth (cm) (on every subsequent debridement)

Postoperative:

General: date of discharge, time of discharge, hospital length of stay, intensive care unit length of stay, (ICU LOS), ventilator days, transfer back to ICU, time of drain removal and mortality. Antibiotics (Regimen, combination, duration), hyperbaric oxygen therapy (HBOT) (Y/N), infectious disease consulted (Y/N) Complications: wound infection. Pneumonia, acute kidney injury, multi-organ dysfunction, sepsis, urinary tract infection, venous thrombosis, pulmonary embolism, adult respiratory distress syndrome Disposition: home, acute rehabilitation center, subacute rehabilitation center.

Follow up:

Investigators will follow patients for 1 year after discharge. Follow-up visits are done in the clinic after 2 weekss, 1 month, 2-months, 4-months, 8-months and 1 year of discharge. We will examine surgical site, asses pain, 36-Item Short Form Survey (SF-36) scores

The research staff will review each chart and retrieve the information included in the data collection form (please see attached). After data is collected, the research team along with the Principal Investigator along with all Co-Investigators will analyze the data.

Statistical Analysis Chi-square difference tests will be used to assess significant differences in predictors on categorical outcomes. T-tests will be used to assess mean differences in predictors on continuous outcomes. Univariable and multivariable logistic regression analyses will be conducted for outcomes such as all-cause mortality, pneumonia, sepsis, and multi-organ failure. Univariable and multivariable linear regression will be performed for hospital length of stay.

Being tested
Surgery
Keywords
Necrotizing Soft Tissue Infection; Quality of life

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SurgeryProcedure or surgery

    Also called Quality of life survey

    Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 30-day mortality. (Short term )

    The short term objectives are to evaluate 30-day mortality.

    Measured: 30 days

Secondary outcomes (1)
  1. The quality of life survey (Long Term)

    To measure quality of life survey after NSTI.

    Measured: 1year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Sep 2021
  2. Study start1 Jul 2019
  3. Primary completion1 Sep 2020
  4. Study completion1 Sep 2020

Why it stopped: low accrual rate

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05032625
Sponsor's protocol ID
12943
Status last verified
Aug 2021
First submitted
13 Aug 2020
Last updated
2 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Necrotizing Soft Tissue Infection, run by New York Medical College at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 2 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: low accrual rate). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

30-day mortality. (Short term ) (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in